Showing 20 of 84 recruiting trials for “primary-plasmacytoma-of-the-bone”
RecruitingNCT07225738 ↗
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
👨⚕️ Dr Julie Côté, MD,FRCPC, CHU de Québec-Université Laval📍 1 site📅 Started Jan 2026View details ↗
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
👨⚕️ Jessica Hahne, MA, MPH, Washington University School of Medicine📍 1 site📅 Started Dec 2025View details ↗
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
🏥 The First Affiliated Hospital with Nanjing Medical University📍 5 sites📅 Started Dec 2025View details ↗
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
🏥 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.📍 14 sites📅 Started Dec 2025View details ↗
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
👨⚕️ Wenbin Qian, Dr., Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Nov 2025View details ↗
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
👨⚕️ Peipei Ye, The Affiliated People's Hospital of Ningbo University📍 1 site📅 Started Oct 2025View details ↗
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
RecruitingNCT07051850 ↗
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
👨⚕️ Pengcheng He, M.D. Ph.D., First Affiliated Hospital Xi'an Jiaotong University📍 1 site📅 Started Jul 2025View details ↗
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
👨⚕️ Zainab Shahid, MBBS, Memorial Sloan Kettering Cancer Center📍 8 sites📅 Started May 2025View details ↗
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Page 1 of 5Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →